Nothing Special   »   [go: up one dir, main page]

GB1553595A - Pyrrolidones and process for their manufacture - Google Patents

Pyrrolidones and process for their manufacture

Info

Publication number
GB1553595A
GB1553595A GB26564/76A GB2656476A GB1553595A GB 1553595 A GB1553595 A GB 1553595A GB 26564/76 A GB26564/76 A GB 26564/76A GB 2656476 A GB2656476 A GB 2656476A GB 1553595 A GB1553595 A GB 1553595A
Authority
GB
United Kingdom
Prior art keywords
formula
properties
pyrrolidones
image
hand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB26564/76A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of GB1553595A publication Critical patent/GB1553595A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Novel pyrrolidones of formula I are prepared by reducing a corresponding ketocarbonyl compound of formula XXVIII. The symbols in formula I have the meaning given in Patent Claim 1. The resulting compounds of formula I are distinguished, on the one hand, by spasmogenic properties and on the other hand by spasmolytic properties, for example by bronchodilatory, blood pressure-lowering (anti-hypertensive), gastric juice secretion-inhibiting and abortive properties. They may therefore be used as medicaments. <IMAGE> <IMAGE>
GB26564/76A 1975-06-27 1976-06-25 Pyrrolidones and process for their manufacture Expired GB1553595A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19752528664 DE2528664A1 (en) 1975-06-27 1975-06-27 PYRROLIDONE AND THE METHOD FOR MANUFACTURING THEIR

Publications (1)

Publication Number Publication Date
GB1553595A true GB1553595A (en) 1979-09-26

Family

ID=5950059

Family Applications (1)

Application Number Title Priority Date Filing Date
GB26564/76A Expired GB1553595A (en) 1975-06-27 1976-06-25 Pyrrolidones and process for their manufacture

Country Status (14)

Country Link
JP (1) JPS525764A (en)
AT (1) AT365575B (en)
BE (1) BE843505A (en)
CH (1) CH623809A5 (en)
DE (1) DE2528664A1 (en)
DK (1) DK287476A (en)
ES (1) ES449095A1 (en)
FR (1) FR2316943A1 (en)
GB (1) GB1553595A (en)
IL (1) IL49916A0 (en)
LU (1) LU75235A1 (en)
NL (1) NL7606773A (en)
SE (1) SE7607331L (en)
ZA (1) ZA763802B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009872A1 (en) 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US6642266B2 (en) 1999-12-22 2003-11-04 Pfizer Inc. EP4 receptor selective agonists in the treatment of osteoporosis
US6747054B2 (en) 2000-11-27 2004-06-08 Pfizer Inc. EP4 receptor selective agonists in the treatment of osteoporosis
US6849657B2 (en) 2001-07-16 2005-02-01 Syntex (U.S.A.) Llc 2-pyrrolidone derivatives as prostanoid agonists
US6900336B2 (en) 2001-07-16 2005-05-31 Syntex (U.S.A.) Llc 8-aza-11-deoxy prostaglandin analogues
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7271183B2 (en) 2003-01-10 2007-09-18 Roche Palo Alto Llc 2-Piperidone derivatives as prostaglandin agonists
US9180116B2 (en) 2012-07-19 2015-11-10 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9688627B2 (en) 2013-03-15 2017-06-27 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US10729810B2 (en) 2013-07-19 2020-08-04 Cayman Chemical Company, Inc Methods, systems, and compositions for promoting bone growth

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE423813B (en) * 1976-08-06 1982-06-07 Pfizer PROCEDURE FOR THE PREPARATION OF 1,5-DISUBSTITUTED PYRROLIDONS WITH THERAPEUTICAL PROPERTIES
US4772601A (en) * 1988-01-25 1988-09-20 Hoechst-Roussel Pharmaceuticals, Inc. 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use
WO2002024647A1 (en) * 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642266B2 (en) 1999-12-22 2003-11-04 Pfizer Inc. EP4 receptor selective agonists in the treatment of osteoporosis
US6747054B2 (en) 2000-11-27 2004-06-08 Pfizer Inc. EP4 receptor selective agonists in the treatment of osteoporosis
US7192979B2 (en) 2000-11-27 2007-03-20 Pfizer Inc. EP4 receptor selective agonist in the treatment of osteoporosis
US6849657B2 (en) 2001-07-16 2005-02-01 Syntex (U.S.A.) Llc 2-pyrrolidone derivatives as prostanoid agonists
US6900336B2 (en) 2001-07-16 2005-05-31 Syntex (U.S.A.) Llc 8-aza-11-deoxy prostaglandin analogues
WO2003009872A1 (en) 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US7608637B2 (en) 2001-07-23 2009-10-27 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient
EP2255829A2 (en) 2001-07-23 2010-12-01 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
US8207223B2 (en) 2001-07-23 2012-06-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US7271183B2 (en) 2003-01-10 2007-09-18 Roche Palo Alto Llc 2-Piperidone derivatives as prostaglandin agonists
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US9180116B2 (en) 2012-07-19 2015-11-10 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9440919B2 (en) 2012-07-19 2016-09-13 Cayman Chemical Company, Inc. Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
US9487478B2 (en) 2012-07-19 2016-11-08 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9701630B2 (en) 2012-07-19 2017-07-11 Cayman Chemical Company, Inc. Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
US10556862B2 (en) 2012-07-19 2020-02-11 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US11066361B2 (en) 2012-07-19 2021-07-20 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US11884624B2 (en) 2012-07-19 2024-01-30 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9688627B2 (en) 2013-03-15 2017-06-27 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US11345690B2 (en) 2013-03-15 2022-05-31 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US10729810B2 (en) 2013-07-19 2020-08-04 Cayman Chemical Company, Inc Methods, systems, and compositions for promoting bone growth

Also Published As

Publication number Publication date
NL7606773A (en) 1976-12-29
SE7607331L (en) 1976-12-28
JPS525764A (en) 1977-01-17
LU75235A1 (en) 1977-03-16
FR2316943B1 (en) 1978-11-03
ATA467976A (en) 1981-06-15
IL49916A0 (en) 1976-08-31
BE843505A (en) 1976-12-28
AT365575B (en) 1982-01-25
FR2316943A1 (en) 1977-02-04
ZA763802B (en) 1977-05-25
ES449095A1 (en) 1977-12-16
DE2528664A1 (en) 1977-01-13
CH623809A5 (en) 1981-06-30
DK287476A (en) 1976-12-28

Similar Documents

Publication Publication Date Title
GB1553595A (en) Pyrrolidones and process for their manufacture
JPS5251327A (en) 3-trihydroxygermylpropionic acid and its salts and process for prepari ng the same
CA934758A (en) Process for the preparation of unsymmetrical 1,4-dihydropyridine 3,5-dicarboxylates
PH13353A (en) Process for the preparation of s-triazolo(%,*&#39;)benzothiazole
JPS5210221A (en) Process for preparation of perfluoroalkylethers containing fluorosulfo nyl group
JPS5257130A (en) Process for preparation of methylphenols
JPS51143669A (en) A process for preparing 1,2,4- oxadiazole derivatives
HUT49125A (en) Process for producing new 2-thiazolidinone derivatives and pharmaceutical compositions containing them
GR3003638T3 (en)
JPS52248A (en) Process for preparing omega-aminoalkoxy biphenyls and their acid adducts
JPS5227734A (en) Process for preparation of 2,6-dichloro- 4-methylphenol
JPS51113870A (en) A process for secretin synthesis
CH613203A5 (en) Process for the preparation of 4,4-diphenylcyclohexylpiperidine
JPS51149210A (en) Process for preparation of tetrafluoroethylene oligomers
EP0118732A3 (en) An anthracycline compound, a process for the production thereof, a pharmaceutical composition containing the same and its use as a medicament
IL82936A (en) 4-benzyloxy-3-pyrrolin-2-one,process for the preparation thereof and the use thereof for the preparation of tetramic acid
JPS5242867A (en) Process for preparation of 17alpha -(3-hydroxypropyl)- 17beta-hydroxy-androsto- 4 -ene-3-one
JPS51121591A (en) Process for preparing heat resistant acylases
JPS51143678A (en) A process for preparing carbostyril derivatives
JPS5212107A (en) Process for preparation of farnesol or its 10,11-isopropylidenedioxy d erivative
JPS51148697A (en) Process for production of anhydrous al fluoride
JPS5233623A (en) Process for preparation of fluorosufonylehters
JPS51133296A (en) Processes for preparing 7-acylamino- 3-hydroxymethyl-2-cephem-4-carbox ylic acid derivatives
JPS5246023A (en) Process for preparation of organosulfinic acid salts
JPS51150590A (en) A process for preparing water-resistant pullulan

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee